Hedeker Wealth LLC Decreases Stock Position in Vertex Pharmaceuticals Incorporated $VRTX

Hedeker Wealth LLC lessened its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 2.4% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 8,791 shares of the pharmaceutical company’s stock after selling 216 shares during the period. Hedeker Wealth LLC’s holdings in Vertex Pharmaceuticals were worth $3,914,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also recently made changes to their positions in VRTX. Vanguard Group Inc. lifted its position in shares of Vertex Pharmaceuticals by 1.0% in the first quarter. Vanguard Group Inc. now owns 23,491,161 shares of the pharmaceutical company’s stock worth $11,388,985,000 after buying an additional 232,873 shares in the last quarter. Jennison Associates LLC raised its holdings in shares of Vertex Pharmaceuticals by 21.5% during the 2nd quarter. Jennison Associates LLC now owns 6,151,505 shares of the pharmaceutical company’s stock worth $2,738,650,000 after acquiring an additional 1,089,063 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Vertex Pharmaceuticals by 2.9% during the 2nd quarter. Geode Capital Management LLC now owns 5,928,747 shares of the pharmaceutical company’s stock valued at $2,627,135,000 after acquiring an additional 166,987 shares during the last quarter. Alliancebernstein L.P. grew its holdings in shares of Vertex Pharmaceuticals by 0.9% in the first quarter. Alliancebernstein L.P. now owns 3,953,512 shares of the pharmaceutical company’s stock valued at $1,916,742,000 after purchasing an additional 33,492 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD grew its holdings in shares of Vertex Pharmaceuticals by 72.5% in the first quarter. Price T Rowe Associates Inc. MD now owns 2,917,227 shares of the pharmaceutical company’s stock valued at $1,414,331,000 after purchasing an additional 1,226,527 shares in the last quarter. 90.96% of the stock is owned by institutional investors.

Vertex Pharmaceuticals Stock Performance

VRTX opened at $437.15 on Friday. The stock’s 50 day moving average price is $408.04 and its 200-day moving average price is $427.31. Vertex Pharmaceuticals Incorporated has a one year low of $362.50 and a one year high of $519.68. The stock has a market cap of $110.91 billion, a price-to-earnings ratio of 31.25 and a beta of 0.36.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings results on Monday, November 3rd. The pharmaceutical company reported $4.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.58 by $0.22. The firm had revenue of $3.08 billion during the quarter, compared to analyst estimates of $3.05 billion. Vertex Pharmaceuticals had a return on equity of 23.91% and a net margin of 31.86%.Vertex Pharmaceuticals’s quarterly revenue was up 11.0% compared to the same quarter last year. During the same period last year, the company earned $4.38 EPS. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, analysts predict that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have commented on VRTX. Scotiabank assumed coverage on shares of Vertex Pharmaceuticals in a research report on Thursday. They set a “sector outperform” rating and a $495.00 price objective for the company. Barclays upped their target price on shares of Vertex Pharmaceuticals from $408.00 to $414.00 and gave the company an “equal weight” rating in a research report on Tuesday, November 4th. HC Wainwright reduced their price objective on Vertex Pharmaceuticals from $550.00 to $478.00 and set a “buy” rating on the stock in a research note on Tuesday, August 5th. JPMorgan Chase & Co. upped their price objective on Vertex Pharmaceuticals from $517.00 to $530.00 and gave the company an “overweight” rating in a research report on Wednesday, October 8th. Finally, BMO Capital Markets set a $530.00 target price on Vertex Pharmaceuticals and gave the stock an “outperform” rating in a report on Tuesday, August 5th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and eleven have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $491.95.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.